We attempted to investigate the potential of agonists of CMKLR1 in the treatment of obesity using chemerin and the C-terminal peptides described here, by following the approach used by others to demonstrate that the stable C-9 analogue is active in vivo. This evidence concerns the gene CMKLR1 and obesity due to melanocortin 4 receptor deficiency.